Pharma Marketletter - Biovail gets US approval for long-acting Cardizem LA; launch in April.
Canada’s Biovail has achieved a significant milestone with the US approval of Cardizem LA (diltiazem), the first drug developed under a New Drug Application that the company will launch directly to physicians. Cardizem LA is a graded-release formulation of the calcium channel blocker that provides 24-hour control of blood pressure in patients …
Related Results
Cardizem in CanadaCardizem settlementBiovail to market CardizemThose Cardizem Cd ads…Teva launches generic version of Cardizem CD
Want to read the whole article? You can purchase it here. It’s quick and easy.
